Clinical Trial

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Name: A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma — clinical trial record (NCT07439653)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Protocol Amendment History 2 changes

critical Recruitment opened 2026-06-12

notable Trial sites expanded: 0 -> 3 locations 2026-06-12

Trial Details

NCT Number	NCT07439653
Lead Sponsor	TORL Biotherapeutics, LLC
Conditions	Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Enrollment	155 participants
Start Date	2026-03-31
Primary Completion	2029-03-31 (estimated)
Study Completion	2029-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-11